L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
EFFACLAR DUO+M CLINICAL STUDY RESULTS: EFFICACY AND ANTI-RELAPSE ACTION
- 4min
- Jul. 2023
- Supported by
Acne is one of the most common skin disorders clearly impacting people’s self-confidence and daily life. Therefore, La Roche-Posay focuses on finding innovative solutions to manage acne-prone skin1.
La Roche-Posay evaluated the efficacy of EFFACLAR DUO+M on multiple clinical signs and an anti-imperfections efficacy from only 8H was observed in the subjects.2
Another clinical study was conducted on 45 subjects and twice daily application of Effaclar DUO+M resulted in a visible reduction of imperfections on day 3 or 4, proven on all phototypes.3
EFFACLAR DUO+M has a proven long-term efficacy. Subjects included in the study where both female and male and where categorized phototype I to VI. The subjects applied EFFACLAR DUO+M twice daily for 56 days.4
EFFACLAR DUO+M reduces acne severity and PIH while also preventing relapses.
On D28:
On D56:
As an example, the visible improvement of phototype I and IV are shown7:
La Roche-Posay evaluated the efficacy of EFFACLAR DUO+M on multiple clinical signs and an anti-imperfections efficacy from only 8H was observed in the subjects.2
Another clinical study was conducted on 45 subjects and twice daily application of Effaclar DUO+M resulted in a visible reduction of imperfections on day 3 or 4, proven on all phototypes.3
EFFACLAR DUO+M has a proven long-term efficacy. Subjects included in the study where both female and male and where categorized phototype I to VI. The subjects applied EFFACLAR DUO+M twice daily for 56 days.4
EFFACLAR DUO+M reduces acne severity and PIH while also preventing relapses.
On D28:
- -57% inflammatory lesions4
- -56% retentional lesions5
On D56:
- -42% PIH4
- 3 months anti-relapse6
As an example, the visible improvement of phototype I and IV are shown7:
Dermo cosmetics have an important role in adjunctive therapy to acne treatments. EFFACLAR DUO+M boosts the efficacy of benzoyl peroxide (BPO), proven in a parallel randomized controlled study with 3 groups.
The differences in results between these 3 groups were evaluated and represented in the graph.
Results show a superiority of EFFACLAR DUO+M in adjunct therapy to BPO compared to BPO alone. The efficacy of BPO is boosted by EFFACLAR DUO+M with a – 86% reduction in the number of skin lesions on D56.
EFFACLAR DUO+M has a proven action in adjunctive therapy to all major drugs: BPO, adapalene, Epiduo, azelaic acid, retinoids, erythromycin, tretinoin and local antibiotics.
To complete the treatment, maintain the clinical results and to prevent relapses.
Tested on 11 014 patients from 34 different countries of all phototypes.8
In conclusion, EFFACLAR DUO+M:
- Group A: Treatment with EFFACLAR DUO+M
- Group B: Treatment with EFFACLAR DUO+M in adjunct therapy to BPO
- Group C: Treatment with BPO
The differences in results between these 3 groups were evaluated and represented in the graph.
Results show a superiority of EFFACLAR DUO+M in adjunct therapy to BPO compared to BPO alone. The efficacy of BPO is boosted by EFFACLAR DUO+M with a – 86% reduction in the number of skin lesions on D56.
EFFACLAR DUO+M has a proven action in adjunctive therapy to all major drugs: BPO, adapalene, Epiduo, azelaic acid, retinoids, erythromycin, tretinoin and local antibiotics.
To complete the treatment, maintain the clinical results and to prevent relapses.
Tested on 11 014 patients from 34 different countries of all phototypes.8
In conclusion, EFFACLAR DUO+M:
- Shows visible efficacy
- Proves to have a 3-month anti-relapse action
- Completes treatment in adjunctive therapy to all major acne drugs.
REFERENCES
1Vilar GN, Santos LA, Sobral Filho JF. Quality of life, self-esteem and psychosocial factors in adolescents with acne vulgaris. An Bras Dermatol. 2015
2Self-assessment, 100 women, analysis after 1 app
3Clinical study on 45 subjects, 2/day Effaclar Duo+M, mean case at D0/D3 & D0/D4, Unretouched pictures.>
415 patients, phototypes, Ill to V. 2/day, . Half-face DUO(+), Half-face placebo. Lesion count at D28 & D56.
5Clinical study, 45 patients, 1/day effaclar duo(+) & effaclar foaming gel 2/day, 4 weeks.
6Clinical study, 3 months, 25 subjects with Effaclar duo(+) after BPO
7Clinical study, 87 men and women, EFFACLAR DUO+ + EFFACLAR GEL MOUSSANT, 56 days
8Clinical study, China, 64 patients, divided in 3 groups (Group A: Effaclar Duo+, Group B: Effaclar Duo+ with BPO and Group C: BPO). Lesion count on D56.